South Plains Financial, Inc. Announces First Quarter 2020 Earnings Call
LUBBOCK, Texas, April 21, 2020 (GLOBE NEWSWIRE) — South Plains Financial, Inc. (NASDAQ:SPFI) (“South Plains” or the “Company”), the parent […]
VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111
TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded […]
HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases
NEW YORK and VIENNA, Austria, April 21, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing […]
Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial
AT-007 demonstrated rapid and sustained reduction in toxic galactitol levels with no accompanying increase in galactosePositive trend on MRI outcomes, […]
CareDx to Report First Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused […]
Altair Accelerates Simulation-Driven Design in Latest Release of Altair Inspire™
TROY, Mich., April 21, 2020 (GLOBE NEWSWIRE) — Altair, (Nasdaq: ALTR) a global technology company providing solutions in product development, […]
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
BOSTON, April 21, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today […]
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpointsIbrexafungerp was generally safe and […]
PacWest Bancorp Announces Results for the First Quarter 2020
Significant ItemsNet Loss of $1.43 Billion, or a Loss of $12.23 Per Diluted ShareRecorded Goodwill Impairment of $1.47 BillionExcluding Goodwill […]
CTG Reports First Quarter 2020 Results
Operating Income Increased More Than 80%, or $0.9 Million, Year-over-YearAchieved GAAP EPS of $0.08; non-GAAP EPS of $0.10BUFFALO, N.Y., April […]
